1. Home
  2. CAVA vs PRAX Comparison

CAVA vs PRAX Comparison

Compare CAVA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CAVA Group Inc.

CAVA

CAVA Group Inc.

HOLD

Current Price

$79.13

Market Cap

8.1B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$325.47

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAVA
PRAX
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
9.6B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
CAVA
PRAX
Price
$79.13
$325.47
Analyst Decision
Buy
Strong Buy
Analyst Count
20
15
Target Price
$86.47
$572.13
AVG Volume (30 Days)
3.6M
364.5K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.54
N/A
Revenue
$1,179,664,000.00
N/A
Revenue This Year
$25.29
N/A
Revenue Next Year
$20.84
$6,395.88
P/E Ratio
$143.19
N/A
Revenue Growth
22.41
N/A
52 Week Low
$43.41
$26.70
52 Week High
$97.98
$354.87

Technical Indicators

Market Signals
Indicator
CAVA
PRAX
Relative Strength Index (RSI) 61.60 53.52
Support Level $78.03 $290.36
Resistance Level $90.59 N/A
Average True Range (ATR) 3.99 18.34
MACD 0.95 -2.56
Stochastic Oscillator 71.21 57.24

Price Performance

Historical Comparison
CAVA
PRAX

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: